Salts of Ruxolitinib and Crystalline Forms Thereof
AssigneeApotex Inc.
InventorsFabio E. S. Souza, Alexander J. Stirk, Avedis Karadeolian, Allan W. Rey
Life of this patent
Estimating the term…
Abstract
The present invention provides ruxolitinib salts and crystalline forms thereof, pharmaceutical compositions including these salts and crystalline forms thereof, and the use of these salts in the treatment of acute graft versus host disease, polycythemia vera, myelofibrosis, and atopic dermatitis.
Claims29
A mesylate salt of ruxolitinib.
A salt of ruxolitinib selected from the group consisting of an edisylate salt of ruxolitinib, a napadisylate salt of ruxolitinib and an acesulfame salt of ruxolitinib.
(canceled)
13-17. (canceled)
The napadisylate salt of ruxolitinib of claim 472, wherein the molar ratio of ruxolitinib to 1,5-naphthalenedisulfonic acid is approximately 1:1 and the napadisylate salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 2θ (±0.2°), at 7.2°, 9.5°, and 15.7°.
(canceled)
21-27. (canceled)
31-34. (canceled)
37-40. (canceled)
Dependencies are inferred from the claim text.